Ligand Pharmaceuticals logo
Ligand Pharmaceuticals
LGND | NASDAQ
Chart Builder DCF Calculator
$301.71
-$7.08 (-2.29%)
At close: Nov 16, 2026, 4:00 PM ET
$300.00
-$1.71 (-0.57%)
After-hours: Nov 16, 2026, 7:38 PM ET

Ligand Pharmaceuticals Company Profile

Company profile explained

Company Profile

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Key Executives

Name Position
Todd C. Davis Chief Executive Officer & Director
Andrew T. Reardon Chief Legal Officer & Secretary
Octavio Espinoza Chief Financial Officer
Karen R. Reeves Senior Vice President of Investments & Head of Clinical Strategy
Keith Marschke Senior Vice President of Biology & Scientific Affairs
Marjorie Fackovec Head of People Operations
Melanie J. Herman Executive Director of Investor Relations and Financial Planning & Analysis
Paul J. Hadden Senior Vice President of Investments & Business Development
Richard Baxter Senior VP of Investment Operations
Vincent D. Antle Senior Vice President of Technical Operations & QA - Capitsol

Latest SEC Filings

Date Type Title
Oct 30, 2026 10-Q Quarterly Report
Oct 29, 2026 8-K Current Report
Oct 06, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 24, 2026 8-K Current Report
Sep 22, 2026 8-K Current Report
Sep 14, 2026 4 Filing
Sep 08, 2026 4 Filing
Sep 02, 2026 8-K/A [Amend] Current Report
Aug 14, 2026 4 Filing
View All SEC Filings ➞
Ligand Pharmaceuticals
Ligand Pharmaceuticals logo
Country United States
IPO Date Nov 18, 1992
Industry Biotechnology
Sector Healthcare
Employees 47
CEO Todd C. Davis

Contact Details

555 Heritage Drive Jupiter, Florida 33458 United States

Stock Details

Ticker Symbol LGND
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000886163
CUSIP Number 53220K504
ISIN Number US53220K5048
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.